General information and education, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Always consult a SEBI-registered adviser.
1. At a Glance
Vasa Denticity sells dental consumables, instruments and equipment to dentists through an online store. Standalone revenue for the three months to June 2026 was ₹82.17 crore. That compares with ₹60.02 crore a year earlier, a rise of 36.9%. Operating profit came in at ₹5.08 crore, against ₹3.16 crore. Net profit rose 46.0% over the same period to ₹4.19 crore. Earnings per share, the profit attached to each share, was ₹2.42.
The previous quarter is the one that repays a second look. The three months to March 2026 produced operating profit of ₹0.22 crore. Revenue that quarter was ₹72.41 crore, which works out at a 0.30% operating margin. That is the financial equivalent of running a full lap and finishing at the starting line. The operating margin in the three months to June 2026 was 6.18%.
The twelve months before this quarter were busy in the way that generates a lot of PDFs. In August 2025 the company announced the purchase of 51% of IDS Denmed. The agreed consideration for that stake was ₹128 crore. On 8 May 2026 the company disclosed that both parties had mutually decided not to proceed. The chief financial officer resigned in March 2026, and a successor was appointed in May 2026. An independent director resigned on 7 August 2026. Crisil, a credit-rating agency, had parked its rating on Watch Developing throughout. It reaffirmed Crisil BBB and reattached a Stable outlook on 4 June 2026.
Underneath the paperwork, the business kept shipping dental consumables to dentists. The company’s investor update counts 1.89 lakh orders in the quarter. Working capital days measure how long cash sits in stock and unpaid bills. The figure for the year to March 2026 was 189 days, up from 95.
2. Introduction
Vasa Denticity Limited was incorporated in 2016 and is promoted by Dr Vikas Agarwal and Mr Sandeep Aggarwal. It sells dental products: consumables, instruments, equipment and accessories. Selling happens principally through the online portal Dentalkart.com and the Dentalkart mobile application. The company listed on NSE Emerge, the exchange’s platform for smaller companies, under the symbol DENTALKART. The offering raised ₹54.5 crore for working capital, brand-building spend, general corporate purposes and offer expenses. A later preferential allotment, meaning shares sold directly to chosen buyers, raised ₹85 crore. Those buyers were Malabar Investments and WhiteOak Capital Asset Management.
The revenue line since then has grown at the pace that makes founders talk in five-year numbers. Standalone revenue was ₹30.42 crore in the year to March 2020. It was ₹76.92 crore in the year to March 2022. It reached ₹169.73 crore two years later, and ₹276.62 crore in the year to March 2026. Crisil, a credit-rating agency, records a three-year revenue CAGR of around 31% to March 2026. CAGR is the average yearly pace of growth across that stretch. Crisil attributes the pace to a rising count of catalogue items, order inflow and a widening customer base.
The group has been acquiring subsidiaries the way it acquires catalogue lines. Waldent Innovations Pvt Ltd was established in August 2023. Smileworks Pvt Ltd, which delivers dental prostheses and restorations, was incorporated in November 2024. Dentalkart Distribution UK Limited appears in the consolidated results for the June 2026 quarter. Crisil consolidates the parent with Waldent and Smileworks as the VDL group.
Recent corporate events run in order. Malabar India Fund converted warrants worth ₹30.99 crore in August 2025, warrants being rights to buy shares later. An extraordinary general meeting in October 2025 reclassified promoter-group shares into the public category. All votes cast were in favour. The IDS Denmed withdrawal followed in May 2026. The finance chief’s post passed from Mr Gaurav Aggarwal to Mr Sandeep Aggarwal on 26 May 2026. Audited results for the year to March 2026 were approved on 30 June 2026, with an unmodified auditor opinion, meaning the auditor raised no exception. Mr Sandeep Aggarwal, co-founder and Whole-Time Director, was re-appointed by rotation on 7 August 2026. The company discloses him as the brother of Dr Vikas Agarwal.
The annual figures those events sit around are revenue of ₹276.62 crore and net profit of ₹10.78 crore.
US
Now live
US Stocks terminal is live
13,000+ US tickers · EDGAR fundamentals · screener and filings feed — the same terminal, for American markets.
Explore →
3. Business Model: WTF Do They Even Do?
The company runs an e-commerce store for teeth. Not the teeth themselves, but the entire industrial hinterland behind them.
The catalogue is the business. Crisil, a credit-rating agency, counts around 470 domestic and international brands on the platform. It also counts more than 23,000 dental products, nearly all of them destined for a space about the size of a matchbox. Screener’s commentary lists the core portfolio as consumables, instruments, small and large equipment, and lab consumables. The same list adds lab equipment, implants and aligners, plus specialty items such as clear aligners and digital workflow tools. The specialisations run across orthodontics, endodontics, oral surgery and diagnosis. Treatment and aesthetics complete the set: six disciplines, one shopping cart.
Consumables made up 71.5% of revenue in the three months to December 2024. Equipment was 23.4% of that mix and instruments 5.1%. The machine that gets discussed at investor meetings is the equipment, and the box of burs pays the electricity bill. Management’s framing on the August 2026 call is consistent with that split. It says consumables carry the highest margins. It puts gross margin on high-ticket digital and equipment sales at roughly 10 to 15%. Management positions digital dentistry as a relationship driver that pulls recurring consumables behind it, rather than as a margin product.
Roughly thirty-plus of the brands are owned in-house. Third parties manufacture them to specifications set by the company’s own research team. The rest of the shelf carries other people’s labels: Mani, 3M,
